Evangelos Terpos

Professor of Hematology

National and Kapodistrian University of Athens - Faculty of Medicine

Greece

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Evangelos Terpos is a faculty member in the Department of Hematology at the National and Kapodistrian University of Athens - Faculty of Medicine in Greece. His research primarily focuses on multiple myeloma, including its treatment efficacy, management of associated ocular events, and the implications of cytogenetics on patient outcomes. He has contributed to several key publications, including consensus statements and systematic reviews guiding clinical practices in hematology.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Ioannis Ntanasis-Stathopoulos

National and Kapodistrian University of Athens

GREECE

View details

National and Kapodistrian University of Athens

GREECE

View details

Nikolaos Thomaidis

PROFESSOR

National and Kapodistrian University of Athens

GREECE

View details

Efstathios Kastritis

Professor

National and Kapodistrian University of Athens

GREECE

View details

DIMITRIOS VASSILOPOULOS

Professor of Medicine-Rheumatology

National and Kapodistrian University of Athens - Faculty of Medicine

GREECE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Evangelos Terpos

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events

European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma

EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials

Elucidating DNA Damage-Dependent Immune System Activation

Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials

Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies

Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management

Metabolomics Point out the Effects of Carfilzomib on Aromatic Amino Acid Biosynthesis and Degradation

Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus

Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study

Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

Receptor-Binding-Domain-Specific B Cell Responses Induced by mRNA Immunization against SARS-CoV-2

Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting

XBB.1.5 neutralizing antibodies upon bivalent COVID‐19 vaccination are similar to XBB but lower than BQ.1.1

Collaborators (11)

Ioannis Ntanasis-Stathopoulos

Maria Geropeppa

Meletios Dimopoulos

Francesca Gay

Despina Fotiou

Argiris Symeonidis

Evagelos Gikas

Ioannis P. Trougakos

Nikolaos Thomaidis

Efstathios Kastritis

DIMITRIOS VASSILOPOULOS

Make your next move.